Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

nowra chemical manufacturers pty ltd t/a nowchem pharma - bemotrizinol,diethylamino hydroxybenzoyl hexyl benzoate,methylene bis-benzotriazolyl tetramethylbutylphenol,octyl methoxycinnamate,phenylbenzimidazole sulfonic acid,zinc oxide -

Amerika Syarikat - Inggeris - NLM (National Library of Medicine)

vivier pharma, inc. - 2.5% avobenzone, 5.5% octinoxate, 2.0% phenylbenzimidazole-5-sulfonic acid - sunscreen • helps prevent sunburn • provides broad-spectrum uva/uvb protection • ideal for daily use; can be applied under makeup • optimal for post-care or on sensitive skin

Amerika Syarikat - Inggeris - NLM (National Library of Medicine)

cvs pharmacy - titanium dioxide 3.0%, zinc oxide 10.0% - sunscreen - helps prevent sunburn - if used as directed with other sun protection measures (see directions ), decreases the risk of skin cancer and early skin aging caused by the sun - on damaged or broken skin. - rash occurs.

Amerika Syarikat - Inggeris - NLM (National Library of Medicine)

sage pharmaceuticals inc - titanium dioxide   11.3% - sunscreen hva / uvb protection - tear-free formula - paraben free - hypoallergenic - fragrance free avoid contact with eyes. in case of severe irritation, stop usage immediately and consult a doctor.

Amerika Syarikat - Inggeris - NLM (National Library of Medicine)

sage pharmaceuticals inc - titanium dioxide   11.3% - sunscreen uva / uvb / hev protection avoid contact with eyes. in case of severe irritation, stop usage immediately and consult a doctor.

Kesatuan Eropah - Inggeris - EMA (European Medicines Agency)

atnahs pharma netherlands b.v. - solriamfetol hydrochloride - narcolepsy; sleep apnea, obstructive - psychoanaleptics, - sunosi is indicated to improve wakefulness and reduce excessive daytime sleepiness in adult patients with narcolepsy (with or without cataplexy).sunosi is indicated to improve wakefulness and reduce excessive daytime sleepiness (eds) in adult patients with obstructive sleep apnoea (osa) whose eds has not been satisfactorily treated by primary osa therapy, such as continuous positive airway pressure (cpap). 

Amerika Syarikat - Inggeris - NLM (National Library of Medicine)

valeant pharmaceuticals - titanium dioxide (unii: 15fix9v2jp) (titanium dioxide - unii:15fix9v2jp), zinc oxide (unii: soi2loh54z) (zinc cation - unii:13s1s8sf37) - titanium dioxide 4.9 g in 100 g - titanium dioxide 4.9%                             sunscreen zinc oxide 4.7%                                       sunscreen - helps prevent sunburn - if used as directed with other sun protection messures (see ​directions ​) decreases the risk of skin cancer and early skin aging caused by sun.

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - amoxicillin trihydrate, quantity: 57.8 mg/ml (equivalent: amoxicillin, qty 50 mg/ml) - suspension, powder for - excipient ingredients: sorbitol; colloidal anhydrous silica; sunset yellow fcf; sodium citrate dihydrate; xanthan gum; saccharin sodium; flavour - indications: treatment of the following infections due to susceptible strains of sensitive organisms. note. therapy should be guided by bacteriological studies, including sensitivity tests, and by clinical response. however, in emergency cases where the causative organism has not been identified, therapy with amoxycillin may be useful. clinical judgement will decide whether combination with another antibiotic would provide a sufficiently broad spectrum of activity pending sensitivity test results. skin and skin structure: staphylococcus, non-penicillinase producing; streptococcus; e. coli (see microbiology). respiratory (acute and chronic): h. influenzae; streptococcus; strep. pneumoniae; staphylococcus, nonpenicillinase producing; e. coli (see microbiology). genitourinary tract (complicated and uncomplicated, acute and chronic): e. coli (see microbiology), p. mirabilis and strep. faecalis. gonorrhoea: n. gonorrhoeae (nonpenicillinase producing). prophylaxis of endocarditis: amoxycillin may be used for the prophylaxis of bacterial endocarditis in individuals at particular risk, such as those with a prosthetic heart valve or those who have previously had endocarditis.

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - amoxicillin trihydrate, quantity: 28.9 mg/ml (equivalent: amoxicillin, qty 25 mg/ml) - suspension, powder for - excipient ingredients: saccharin sodium; sorbitol; colloidal anhydrous silica; xanthan gum; sunset yellow fcf; sodium citrate dihydrate; flavour - indications: treatment of the following infections due to susceptible strains of sensitive organisms. note. therapy should be guided by bacteriological studies, including sensitivity tests, and by clinical response. however, in emergency cases where the causative organism has not been identified, therapy with amoxycillin may be useful. clinical judgement will decide whether combination with another antibiotic would provide a sufficiently broad spectrum of activity pending sensitivity test results. skin and skin structure: staphylococcus, non-penicillinase producing; streptococcus; e. coli (see microbiology). respiratory (acute and chronic): h. influenzae; streptococcus; strep. pneumoniae; staphylococcus, nonpenicillinase producing; e. coli (see microbiology). genitourinary tract (complicated and uncomplicated, acute and chronic): e. coli (see microbiology), p. mirabilis and strep. faecalis. gonorrhoea: n.gonorrhoeae (nonpenicillinase producing). prophylaxis of endocarditis: amoxycillin may be used for the prophylaxis of bacterial endocarditis in individuals at particular risk, such as those with a prosthetic heart valve or those who have previously had endocarditis.

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - epoprostenol sodium, quantity: 0.531 mg (equivalent: epoprostenol, qty 0.5 mg) - injection, powder for - excipient ingredients: sucrose; sodium hydroxide; glycine - epoprostenol sun is indicated for the long-term treatment, via continuous intravenous infusion, in who functional class iii or class iv patients with idiopathic pulmonary arterial hypertension, familial pulmonary arterial hypertension and pulmonary arterial hypertension associated with the scleroderma spectrum of diseases.